Profit before interest, taxes and amortization: i-mabbiopharma.com (IMAB)

Analyzing the EBITDA of I-Mab (IMAB) on GURU.Markets, we see that serves as the final level mark. The growth of I-Mab is based on the success of new antibodies and partnerships in immuno-oncology. However, cross-border logistics complexities and patent disputes are hindering development. The business is currently optimizing R&D processes by switching to regional Asian contractors to minimize external risks.

I-Mab is scaling the development of oncology drugs through a strategic alliance with a global pharma leader, optimizing clinical trial costs. By analyzing absolute EBITDA, investors assess the real cash flow from core operations excluding depreciation and taxes, which allows them to separate speculative market noise from the business's actual ability to generate capital and confirms the company's fundamental stability.